Rexahn Pharmaceuticals to Present at the 2nd Annual Sachs Cancer Bio Partnering & Investment Forum in New York
March 17 2014 - 8:00AM
Business Wire
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage
biopharmaceutical company developing best-in-class therapeutics for
the treatment of cancer, today announced that Vikas Sharma, Ph.D.,
the Company’s Director, Business Development, will present at the
2nd Annual Sachs Cancer Bio Partnering & Investment Forum in
New York on Wednesday, March 19, 2014. Dr. Sharma will also serve
on an expert panel titled "Strategies for small molecules and
biologicals drug development.” The conference will take place at
New York Academy of Sciences, located at 250 Greenwich St, New
York, NY.
The 2nd Annual Sachs Cancer Bio Partnering & Investment
Forum is designed to bring together thought leaders from cancer
research institutes, patient advocacy groups, pharma, and biotech
to facilitate partnering and investments. Over 200 delegates are
expected for one on one partnering meetings, company presentations,
and licensing connections.
About Rexahn Pharmaceuticals, Inc. Rexahn Pharmaceuticals
is a clinical stage biopharmaceutical company dedicated to
developing best-in-class therapeutics for the treatment of cancer.
Rexahn currently has three clinical stage oncology candidates,
Archexin®, RX-3117, and Supinoxin™ (RX-5902), and a robust pipeline
of preclinical compounds to treat multiple types of cancer. Rexahn
has also developed proprietary drug discovery platform technologies
in the areas of Nano-Polymer-Drug Conjugate Systems (NPDCS),
nano-medicines, 3D-GOLD, and TIMES. For more information, please
visit www.rexahn.com.
Safe Harbor To the extent any statements made in this
press release deal with information that is not historical, these
are forward-looking statements under the Private Securities
Litigation Reform Act of 1995. Such statements include, but are not
limited to, statements about Rexahn’s plans, objectives,
expectations and intentions with respect to future operations and
products and other statements identified by words such as “will,”
“potential,” “could,” “can,” “believe,” “intends,” “continue,”
“plans,” “expects,” “anticipates,” “estimates,” “may,” other words
of similar meaning or the use of future dates. Forward-looking
statements by their nature address matters that are, to different
degrees, uncertain. Uncertainties and risks may cause Rexahn’s
actual results to be materially different than those expressed in
or implied by Rexahn’s forward-looking statements. For Rexahn,
particular uncertainties and risks include, among others, the
difficulty of developing pharmaceutical products, obtaining
regulatory and other approvals and achieving market acceptance; the
marketing success of Rexahn’s licensees or sublicensees; the
success of clinical testing; and Rexahn’s need for and ability to
obtain additional financing. More detailed information on these and
additional factors that could affect Rexahn’s actual results are
described in Rexahn’s filings with the Securities and Exchange
Commission, including its most recent annual report on Form 10-K
and subsequent quarterly reports on Form 10-Q. All forward-looking
statements in this news release speak only as of the date of this
news release. Rexahn undertakes no obligation to update or revise
any forward-looking statement, whether as a result of new
information, future events or otherwise.
The Trout Group LLCTricia Truehart,
646-378-2953ttruehart@troutgroup.com
Rexahn Pharmaceuticals, Inc. (AMEX:RNN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Rexahn Pharmaceuticals, Inc. (AMEX:RNN)
Historical Stock Chart
From Sep 2023 to Sep 2024